Compare McKesson Corporation (MCK) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Strategy Inc. — how do they compare? McKesson Corporation trades at $823.62 (market cap $97.35B), while Strategy Inc. trades at $100.77 (market cap $35.47B). The key difference: McKesson Corporation is far larger — about 2.7× Strategy Inc.'s market cap, and McKesson Corporation pays a 0.39% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.
| MCK | MSTR | |
|---|---|---|
Market Cap | $97.35B | $35.47B |
Sector | Health | Technology |
52-Week High | $995.69 | $426.40 |
52-Week Low | $659.01 | $82.31 |
Enterprise Value | $101.98B | $50.50B |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
MSTR trades at $97.77, up 3.08% today, but remains in a bearish technical trend with resistance at $98. The company shows concerning fundamentals with a -2,482% net income margin and negative cash flow from operations of -$67.24M in 2025. Recent earnings missed expectations in two of the last three quarters, though analyst consensus remains bullish with a $237.63 price target representing 143% upside potential from current levels.
While Wall Street maintains a Buy rating (62% of analysts), significant risks include extreme profitability challenges, volatile earnings history, and high debt levels. The stock's valuation appears disconnected from underlying business performance, trading at a low P/E of 5.3 but extremely high P/S of 57.4, suggesting investors are pricing in future growth that current operations don't support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
